Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy

類似資料

• Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
  著者:: Jetty, Vybhav, 等
  出版事項: (2017)
• Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center
  著者:: Shah, Parth, 等
  出版事項: (2016)
• Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
  著者:: Jetty, Vybhav, 等
  出版事項: (2016)
• Associations between Serum 25-hydroxyvitamin D and Lipids, Lipoprotein Cholesterols, and Homocysteine
  著者:: Glueck, Charles J., 等
  出版事項: (2016)
• LDL Cholesterol, Statins And PCSK 9 Inhibitors
  著者:: Gupta, Sanjiv
  出版事項: (2015)